Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center
Articles by Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center
Exploring Emerging Data in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Looking at the Big Picture in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.
Treating Patients Post CAR T Therapy
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
Optimal Approaches to Bridging Therapy in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.
Evaluating CAR T Therapies in Lymphoma
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.
Recommendations for CAR T-Cell Therapy in R/R DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.
Newer Approvals for Previously Treated DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.
DLBCL: Approaches to Treating Patients Ineligible for Transplant
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.
Data From the L-MIND Trial
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).
Recommendations for Second-Line Therapy in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.
Managing Relapsed DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.
Outlook for CNS Lymphoma
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.
DLBCL: Approaching CNS Prophylaxis
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health A panel of experts explain how they approach CNS prophylaxis in DLBCL.
Treatment Considerations in DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.
Treating Newly Diagnosed Patients With DLBCL
ByJohn P. Leonard, MD, Weill Cornell Medicine,Cyrus Khan, MD, West Penn Hospital ,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Greg Nowakowski, MD, Mayo Clinic ,David Rizzieri, MD, Duke Health Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.
Novel Therapies for R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.
CAR T for R/R FL: Treatment Considerations
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.
CAR T-Cell Therapy for R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.
ZUMA-5 in R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.
Treating Follicular Lymphoma With Early Progression
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).
Emerging Therapies for R/R Follicular Lymphoma
ByIan Flinn, MD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.
Case Discussion: 68-Year-Old With R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
R/R Follicular Lymphoma: Testing for EZH2
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.
EZH2 Inhibition in R/R FL: Safety & Efficacy Data
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.
Tazemetostat for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.
R2 Regimen for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.
PI3K Inhibitors for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.
R/R Follicular Lymphoma: Third-Line Treatment Options
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.
Transplantation for R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.
MRD Testing in R/R Follicular Lymphoma
ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,Caron A. Jacobson, MD, Dana-Farber Cancer Institute,Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey,Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center,Krish Patel, MD, Swedish Cancer Institute Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.
Looking at the Big Picture in DLBCL
CAR T for R/R FL: Treatment Considerations
Treating Patients Post CAR T Therapy
Recommendations for Second-Line Therapy in DLBCL
Novel Therapies for R/R Follicular Lymphoma
Treating Follicular Lymphoma With Early Progression